Cyclophosphamide,Fludarabine

DRUG5 trials

Sponsors

Hebei Senlang Biotechnology Inc., Ltd.

Conditions

CD19+ and CD 22+ B-ALLHodgkin's LymphomaLeukemiaLymphomaNon-hodgkin's LymphomaPlasma Cell Tumors

Early Phase 1

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

Hebei Senlang Biotechnology Inc., Ltd.CD19+ and CD 22+ B-ALL

Start: 2021-08-15End: 2023-11-30Target: 100Updated: 2022-02-07

Unknown Phase

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Hebei Senlang Biotechnology Inc., Ltd.Leukemia, Lymphoma

Start: 2020-06-23End: 2025-06-22Target: 30Updated: 2020-10-30

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Hebei Senlang Biotechnology Inc., Ltd.Plasma Cell Tumors

Start: 2020-10-22End: 2025-10-21Target: 60Updated: 2020-12-11

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.Hodgkin's Lymphoma

Start: 2020-10-22End: 2025-10-21Target: 20Updated: 2020-12-29

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.Non-hodgkin's Lymphoma

Start: 2020-10-22End: 2025-10-21Target: 200Updated: 2020-12-14

Related Papers

Tandem CD19/20 CAR-T Showed Durable Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma: Interim Results from a Multicenter Phase I/II Trial

Blood2024-11-051 citations

Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

Frontiers in Immunology2022-10-055 citations